By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Reporting as a public company for the first time, Fluidigm today said that its fourth-quarter revenues increased 36 percent while it trimmed its net loss year over year.

The South San Francisco-based microfluidics and sample preparation technologies firm brought in total revenues of $10.4 million for the three months ended Dec. 31, 2010, compared to $7.6 million for the fourth quarter of 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.